First described in the 4th Century in China, practiced since the 1950’s and re-discovered relatively recently, Fecal Microbiota Transplantation (FMT) or simply Fecal Transplant is a therapeutic approach in which more or less processed fecal material from a single (or multiple) healthy donor(s) is transferred to a diseased individual to restore health. This therapeutic strategy was actually the one that sparked interest in microbiome drug development back in 2013, with the publication of the results of a human trial in which FMT showed extremely efficacious against recurrent Clostridioides difficile infection [3]. Since then, multiple companies and academics have embarked in the development of FMT treatments for different conditions, targeting C. difficile infection and beyond.
Read the full article at the Microbiome Times